News for UCB SA (UCBN.MX)

HSBC analyst Rajesh Kumar has adjusted the price target for UCB (UCBJF), lowering it to EUR 179 from EUR 203, while maintaining a Buy rating on the shares. This

Strong focus on neurology and immunology therapeutic areas.Robust pipeline of innovative drugs and treatments.Risks include regulatory hurdles and competitive

**media[572648]**

European stock markets experienced a downturn, driven by investor concerns over Germany's spending plans, the impact of U.S. economic growth, and tariffs. The S

Revenue Growth: 17% increase, 19% at constant rate, reaching EUR6.150 billion.Net Sales: EUR5.6 billion, 15% growth, 17% at constant rate.Adjusted Gross Margin

Feb 27, 2025 / 01:00PM GMTAntje Witte - Ucb SA - Head of Investor Relations Welcome to the UCB full year 2024 Capital Market Call. My name is Antje. I'm the Hea

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025.

Belgium stocks lower at close of trade; BEL 20 down 0.90%

Belgium stocks higher at close of trade; BEL 20 up 0.43%

Belgium stocks higher at close of trade; BEL 20 up 0.54%

Belgium stocks higher at close of trade; BEL 20 up 0.54%

Belgium stocks lower at close of trade; BEL 20 down 0.64%

Belgium stocks higher at close of trade; BEL 20 up 0.27%

Belgium stocks higher at close of trade; BEL 20 up 0.25%

Belgium stocks higher at close of trade; BEL 20 up 0.07%

Belgium stocks higher at close of trade; BEL 20 up 0.50%

Belgium stocks higher at close of trade; BEL 20 up 0.58%

Belgium stocks lower at close of trade; BEL 20 down 0.14%

Belgium stocks higher at close of trade; BEL 20 up 1.28%